Regulatory Novartis secures pair of regulatory wins for skin disease and malaria treatments Pharmaceutical TechnologyNovartis' Rhapsido has won approval in Europe, while Coartem Baby has received WHO prequalification.Read full story pharminent April 27, 2026 (Last updated: April 27, 2026) Pharmaceutical Technology Novartis’ Rhapsido has won approval in Europe, while Coartem Baby has received WHO prequalification. Read full story Post navigation Previous: New NIHR-funded TRC for Parkinson’s diseaseNext: Eli Lilly acquires Ajax Therapeutics for first-in-class JAK2 inhibitor in myelofibrosis Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026